SIPA1L2 Antibody

What are the primary applications for SIPA1L2 antibodies in research?

SIPA1L2 antibodies are primarily used for Western blot (WB), immunohistochemistry (IHC), immunohistochemistry-paraffin (IHC-P), and ELISA applications. These techniques allow researchers to detect and localize SIPA1L2 in various experimental contexts. For optimal results in IHC-P applications, heat-induced epitope retrieval (HIER) at pH 6 is recommended with antibody dilutions of 1:50-1:200 . In Western blot applications, concentrations of 0.04-0.4 μg/ml are typically effective, though optimization for specific experimental conditions is advisable .

What is the molecular weight of SIPA1L2 and how does this affect antibody detection?

SIPA1L2 has a calculated molecular weight of approximately 190 kDa . When performing Western blot experiments, this high molecular weight necessitates specific technical considerations including longer transfer times, lower percentage SDS-PAGE gels (6-8%), and careful sample preparation to prevent protein degradation. Researchers should also be aware that post-translational modifications might cause shifts in the apparent molecular weight of SIPA1L2 in electrophoresis.

How can researchers validate the specificity of SIPA1L2 antibodies?

To validate SIPA1L2 antibody specificity, researchers should employ multiple complementary approaches:

• Blocking experiments using recombinant SIPA1L2 protein fragments, such as the control fragment mentioned in search result #6

• Comparison of staining patterns across multiple antibodies targeting different epitopes of SIPA1L2

• Use of genetic knockdown/knockout controls when available

• Confirmation of expected molecular weight in Western blot (approximately 190 kDa)

• Co-immunoprecipitation experiments to verify interaction with known binding partners like TrkB

For blocking experiments, a 100x molar excess of the protein fragment control based on antibody concentration and molecular weight is recommended, with pre-incubation for 30 minutes at room temperature .

What are the optimal storage and handling conditions for SIPA1L2 antibodies?

Most SIPA1L2 antibodies should be stored at -20°C for long-term stability . For short-term storage, 4°C is typically acceptable. Most commercial antibodies are supplied in buffer containing preservatives like sodium azide (0.02%) and stabilizers like glycerol (40-50%) . Aliquoting is recommended to avoid repeated freeze-thaw cycles, which can degrade antibody performance. When working with concentrated antibody solutions, researchers should ensure proper dilution in appropriate buffers prior to experimental use.

What are the recommended protocols for coimmunoprecipitation experiments with SIPA1L2 antibodies?

For coimmunoprecipitation of SIPA1L2 and its interaction partners:

• Use cell or tissue lysates prepared with non-denaturing buffers containing appropriate protease inhibitors

• Pre-clear lysates with protein A/G beads to reduce non-specific binding

• Incubate pre-cleared lysates with SIPA1L2 antibody (typically 2-5 μg per 500 μg of protein lysate)

• Capture antibody-protein complexes using Dynabeads Protein A or similar immunoprecipitation systems

• Wash thoroughly to remove non-specific interactions

• Analyze by Western blot using antibodies against suspected interaction partners

This approach has been successfully used to demonstrate interactions between SIPA1L2 and partners such as TrkB, MYH9, and components of the dynein motor complex .

How can researchers investigate the role of SIPA1L2 in TrkB trafficking and signaling?

To study SIPA1L2's role in TrkB trafficking and signaling, researchers can employ several complementary approaches:

• Live imaging: Track retrograde trafficking of TrkB-GFP and tRFP-LC3b in neurons with and without SIPA1L2 expression

• Co-localization studies: Use super-resolution techniques such as STED microscopy to visualize SIPA1L2 and TrkB at axon terminals

• Transport complex isolation: Immunoprecipitate with anti-dynein intermediate chain (DIC) antibodies to isolate complexes containing SIPA1L2, TrkB, and LC3

• Mutagenesis: Introduce mutations in the ActI domain of SIPA1L2 (specifically the 14 amino acids crucial for TrkB binding) to disrupt the SIPA1L2-TrkB interaction

• Binding assays: Use GST-pulldown and MBP fusion proteins to assess direct interactions between SIPA1L2 domains and the cytoplasmic region of TrkB

These methods have revealed that SIPA1L2 connects TrkB-containing amphisomes to dynein motors for retrograde trafficking and regulates signaling at presynaptic boutons during transport .

What experimental approaches can reveal SIPA1L2's RapGAP activity and its regulation?

To assess and characterize SIPA1L2's RapGAP activity:

• Rap1-GTP pulldown assays: Extract SIPA1L2 (wild-type or mutant) from expressing cells and measure its ability to reduce levels of GTP-bound Rap1 using GST-based pulldown matrices

• Negative controls: Use the SIPA1L2-N705A mutant (with an inactive RapGAP domain) as a negative control

• LC3 modulation: Test the effect of recombinant His-LC3b on RapGAP activity by including it in reaction buffers

• Phosphorylation studies: Examine how PKA-dependent phosphorylation at S990 affects RapGAP activity using phosphomimetic (S990D) and phosphodeficient mutants

Research has shown that binding of LC3b to the LIR motif in SIPA1L2's RapGAP domain enhances its catalytic activity, while PKA phosphorylation appears to negatively regulate this activity .

How should researchers approach studying SIPA1L2 as a genetic modifier in Charcot-Marie-Tooth disease?

When investigating SIPA1L2's role as a genetic modifier in CMT1A:

Results from such studies have implicated SIPA1L2 as a potential genetic modifier in CMT1A, offering new pathways for therapeutic interventions .

What might cause variable or inconsistent staining patterns in immunohistochemistry with SIPA1L2 antibodies?

Variable staining patterns may result from several factors:

• Tissue-specific expression: SIPA1L2 shows highest expression in granule cells of the dentate gyrus and cerebellum

• Fixation conditions: Over-fixation may mask epitopes while under-fixation may compromise tissue morphology

• Antigen retrieval: HIER at pH 6 is recommended for most SIPA1L2 antibodies in paraffin sections

• Antibody concentration: Optimal dilutions typically range from 1:50 to 1:200 for IHC-P applications

• Detection systems: Sensitivity of secondary detection systems may affect signal strength

To troubleshoot, researchers should systematically optimize each parameter while including appropriate positive controls, such as brain tissue sections known to express SIPA1L2.

How can researchers distinguish between specific and non-specific bands in Western blot?

To differentiate between specific and non-specific bands:

• Use blocking peptides: Pre-incubate the antibody with a recombinant SIPA1L2 fragment (like the one described in search result #6) to block specific binding

• Include positive controls: Use lysates from cells or tissues known to express SIPA1L2

• Size verification: Confirm that the primary band appears at the expected molecular weight (~190 kDa)

• Compare antibodies: Test multiple antibodies targeting different epitopes of SIPA1L2

• Validate with knockdown: Compare samples with and without SIPA1L2 knockdown/knockout

Non-specific bands might represent cross-reactivity with related proteins (other SIPA1L family members), degradation products, or alternative splice variants.

What experimental controls are essential when studying SIPA1L2's interaction with LC3b and its effect on RapGAP activity?

Essential controls for studying SIPA1L2-LC3b interactions include:

• LIR motif mutants: Express SIPA1L2 with mutations in the LC3-interacting region (LIR motif)

• RapGAP-inactive control: Use the SIPA1L2-N705A mutant as a negative control for RapGAP activity

• Competitive binding assays: Test whether Snapin and LC3b binding to SIPA1L2 are mutually exclusive or can occur simultaneously

• Recombinant protein controls: Include purified LC3b in binding and activity assays to directly assess its effect on RapGAP function

• In vitro GAP assays: Measure GTP hydrolysis rates of recombinant Rap1b with purified SIPA1L2 components

Research has shown that LC3b binding to the RapGAP domain enhances SIPA1L2's catalytic activity, and both Snapin and LC3b can bind to SIPA1L2 concurrently .

What are promising approaches for targeting SIPA1L2 in therapeutic development for CMT1A?

Based on current research, several approaches show therapeutic potential:

• PMP22 expression modulation: Since SIPA1L2 knockdown reduces PMP22 expression in Schwannoma cells, targeting this pathway could help normalize PMP22 levels in CMT1A

• SOX10-regulated network intervention: As SIPA1L2 is part of a myelination-associated coexpressed network regulated by SOX10, targeting this transcriptional network might offer therapeutic benefits

• RapGAP activity modulation: Developing small molecules that modulate SIPA1L2's RapGAP activity could affect downstream signaling relevant to CMT1A pathophysiology

• TrkB signaling enhancement: Since SIPA1L2 regulates TrkB trafficking and signaling, approaches that enhance neurotrophin signaling might be beneficial

These approaches could lead to novel therapies that address the considerable variance in disease expression among CMT1A patients .

What methodological advances would improve the study of SIPA1L2 in amphisome trafficking?

Future methodological advances could include:

• Multi-color live super-resolution imaging: To simultaneously track SIPA1L2, TrkB, LC3, and presynaptic markers in living neurons

• Optogenetic approaches: To temporally control SIPA1L2 activity or interactions at specific subcellular locations

• Proximity labeling techniques: Such as BioID or APEX2 fused to SIPA1L2 to identify the complete amphisome-associated proteome

• Correlative light and electron microscopy: To definitively characterize the ultrastructure of SIPA1L2-positive amphisomes

• CRISPR-based approaches: To create endogenously tagged SIPA1L2 for visualization without overexpression artifacts

These approaches would provide deeper insights into how SIPA1L2 coordinates the balance between retrograde trafficking and local signaling of neurotrophin receptors .